EGFR and non-small cell lung carcinoma: The LUX-Lung 5 trial evaluated afatinib plus chemotherapy vs. single agent chemotherapy in patients with advanced EGFR-mutant NSCLC who had progressed after treatment with first-generation EGFR TKI, chemotherapy, and afatinib [60].